Fig. 8: Inhibition of lactylation or GRAMD1A suppressed the growth of CRC patient-derived xenografts (PDX). | Cell Death & Differentiation

Fig. 8: Inhibition of lactylation or GRAMD1A suppressed the growth of CRC patient-derived xenografts (PDX).

From: KRAS mutation increases histone H3 lysine 9 lactylation (H3K9la) to promote colorectal cancer progression by facilitating cholesterol transporter GRAMD1A expression

Fig. 8

A Image of KRAS mutant PDX treated with GSK2837808A or U18666A. Statistical analysis of tumor B volume and C weight. C Image of KRAS wild-type PDX treated with GSK2837808A or U18666A. Statistical analysis of tumor D volume and E weight. J Immunofluorescence staining of H3K9la levels and Ki-67 expression in KRAS mutant and wild-type PDX treated with GSK2837808A. Scale bar: 100 μm. Statistical immunofluorescence results of G H3K9la levels and H Ki-67 expression. K Immunofluorescence staining of Ki-67 expression in KRAS mutant and wild-type PDX treated with U18666A. Scale bar: 100 μm. Statistical immunofluorescence results of I Ki-67 expression. Values are presented as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, determined by one-way ANOVA (B, C, E, F) and two-tailed Student’s t-test (G–I).

Back to article page